Literature DB >> 814945

Results of the use of a new water-soluble contrast medium (metrizamide) in the posterior fossa of the baboon.

I G Wylie, F Afshar, T H Koeze.   

Abstract

An investigation was made of the use of a new water-soluble contrast material (metrizamide) for posterior-fossa radiography in the baboon. The experiments showed that the concentration of metrizamide needed to produce adequate radiographs from sub-occipital injections into the posterior fossa always produced generalized seizures. Intraventricular injection produced excellent radiographs from metrizamide concentrations, which did not result in either clinical or EEG seizure activity. Seizures, when they occurred, were easily controlled with pentobarbitone and phenytoin. In all the experiments, ECG changes were found, which disappeared after some hours.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 814945     DOI: 10.1259/0007-1285-48-576-1007

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  5 in total

1.  Potentiation of Amipaque epileptogenic activity by neuroleptics.

Authors:  R E Gonsette; J M Brucher
Journal:  Neuroradiology       Date:  1977-08-25       Impact factor: 2.804

2.  Lateral C1-C2 puncture: a technique to reduce adverse reactions in metrizamide sellar cisternography.

Authors:  K Katevuo; I Kuuliala
Journal:  Neuroradiology       Date:  1982       Impact factor: 2.804

3.  Cerebrospinal fluid imaging using serial metrizamide CT cisternography.

Authors:  B P Drayer; A E Rosenbaum; H B Higman
Journal:  Neuroradiology       Date:  1977-03-28       Impact factor: 2.804

4.  Fatal complications after myelography with meglumine diatrizoate.

Authors:  M J Hilz; W Huk; B Schellmann; F Sörgel; K F Druschky
Journal:  Neuroradiology       Date:  1990       Impact factor: 2.804

5.  Metrizamide cisternography and computed tomography for the investigation of pituitary lesions.

Authors:  P Sheldon; A Molyneux
Journal:  Neuroradiology       Date:  1979-02-26       Impact factor: 2.804

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.